gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 12 Nov 2014.


Top mentioned proteins: beta2, HAD, CAN, AGE, Serum albumin
Papers on beta2-microglobulin
High-volume online haemodiafiltration improves erythropoiesis-stimulating agents (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
Pizzarelli et al., Camaiore, Italy. In Nephrol Dial Transplant, 10 Dec 2014
HEP, beta2-microglobulin (b2MG) and C-reactive protein (CRP) were determined every 3 months, and ERI was calculated monthly as the weekly ESA dose per kilogram of body weight divided by Hb level.
Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity.
Dubucquoi et al., Lille, France. In Autoimmun Rev, Sep 2014
In multivariate analysis, beta2-microglobulin levels correlated with disease activity, BAFF levels with severity and sFLC with neither of these.
Beta2-microglobulin as a diagnostic marker in cerebrospinal fluid: a follow-up study.
Lánská et al., Kralupy nad Vltavou, Czech Republic. In Dis Markers, Dec 2013
Beta2-Microglobulin ( β 2-m) is a low molecular weight protein occurring in all body fluids.
[Hypercoagulation syndrome in multiple myeloma].
Mendeleeva et al., In Ter Arkh, Dec 2013
The level of D-dimer was statistically significantly positively correlated with the endogenous thrombin potential and the amount of beta2-microglobulin.
[Clinical value of the determination of markers for endothelial dysfunction (endothelin-1, microalbuminuria) and tubulointerstitial tissue lesion (β2-microglobulin, monocyte chemotactic protein-1) in hypertensive patients with uric acid metabolic disorders].
Balkarov et al., In Ter Arkh, Dec 2013
AIM: To identify the risk factors of kidney injuries in hypertensive patients with uric acid (UA) metabolic disorders in order to choose the optimal management tactics, by analyzing the changes in markers for endothelial dysfunction (endothelin-1 (ET-1), microalbuminuria (MAU), intima-media thickness (IMT)) and tubulointerstitial tissue lesion (beta2-microglobulin (beta2-MG, monocyte chemotactic protein-1 (MCP-1)).
Predictors for the development of non-Hodgkin lymphoma in primary Sjögren's syndrome.
Jonsson et al., Bergen, Norway. In Presse Med, 2012
Among the established predictors for lymphoma development in SS, we recognize recurrent or permanent swelling of major salivary glands (SG), lymphadenopathy, cryoglobulinemia, splenomegaly, low complement levels of C4 and C3, lymphopenia, skin vasculitis or palpable purpura, M-component in serum or urine, peripheral neuropathy, glomerulonephritis and elevated beta2-microglobulin.
Osteo-articular manifestations of amyloidosis.
Grateau et al., Paris, France. In Best Pract Res Clin Rheumatol, 2012
The amyloidosis responsible for osteo-articular manifestations are the AL immunoglobulin amyloidosis, the beta2-microglobulin amyloidosis in patients under haemodialysis and finally the amyloidosis of transthyretin (genetic and senile).
Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury.
Maurer et al., Basel, Switzerland. In Nat Biotechnol, 2010
Whereas urinary clusterin outperformed BUN and SCr for detecting proximal tubular injury, urinary total protein, cystatin C and beta2-microglobulin showed a better diagnostic performance than BUN and SCr for detecting glomerular injury.
Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL).
Stilgenbauer et al., Ulm, Germany. In Best Pract Res Clin Haematol, 2010
In addition, serum markers (e.g., thymidine kinase (TK) and beta2-microglobulin (beta2-MG)), cellular markers (e.g., CD38 and ZAP70) and clinical staging have an impact on outcome in CLL.
[Screening for subclinical complications in children and adolescents with type 1 diabetes: experience acquired in Brussels].
Dorchy, Brussels, Belgium. In Rev Med Brux, 2009
Early microproteinuria is of mixed origin, being both glomerular (microalbumin) and tubular (beta2-microglobulin).
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.
Solal-Céligny et al., Modena, Italy. In J Clin Oncol, 2009
beta2-microglobulin higher than the upper limit of normal, longest diameter of the largest involved node longer than 6 cm, bone marrow involvement, hemoglobin level lower than 12 g/dL, and age older than 60 years were factors independently predictive for PFS.
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
Montserrat et al., Barcelona, Spain. In J Clin Oncol, 2009
Advanced clinical stage, del(17p), or increased serum beta2-microglobulin levels correlated with a lower CR rate.
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
German Chronic Lymphocytic Leukemia Study Group et al., Ulm, Germany. In J Clin Oncol, 2009
Efficacy did not vary significantly in subgroups defined by genetic parameters (in particular, in 17p deletion, 11q deletion, mutated TP53, and unmutated VH), but efficacy was inferior in patients with increased beta2-microglobulin (beta2-MG) and thymidine kinase (TK).
Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry.
Spanish Group for the Study of CNS Disease in NHL et al., Salamanca, Spain. In J Clin Oncol, 2009
Interestingly, in Burkitt lymphoma, presence of CNS disease by FCM could be predicted with a high specificity when increased serum beta2-microglobulin and neurological symptoms coexisted, while peripheral blood involvement was the only independent parameter associated with CNS disease in diffuse large B-cell lymphoma, with low predictive value.
Newly diagnosed multiple myeloma in Taiwan: the evolution of therapy, stem cell transplantation and new treatment agents.
Sung et al., Taipei, Taiwan. In Hematol Oncol Stem Cell Ther, 2008
The new international staging system based on beta2-microglobulin and albumin levels in serum is also very helpful in defining the high-risk group (stage 3).
share on facebooktweetadd +1mail to friends